Reference Detail

Ref Type

PMID

Authors

Kyriakos P. Papadopoulos, Erkut Borazanci, Daniel Von Hoff, Leena Gandhi, Amita Patnaik, Masaya Tachibana, Hamim Zahir, Roohi Gajee, Terri Goldberg, Giorgio Senaldi and Sai-Hong Ou

Title

Abstract CT024: First-in-human phase 1 dose-escalation study of DS-6051b, an oral ROS1 and NTRK inhibitor, in subjects with advanced solid tumors

Journal	Vol	Issue	Date	Pages	Journal Short Title

URL

http://cancerres.aacrjournals.org/content/76/14_Supplement/CT024.short

Abstract Text

Cancer Res July 15 2016 (76) (14 Supplement) CT024

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach
No data available in table

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role
No data available in table

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
No data available in table

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
No data available in table

Filter rows:

Showing 0 to 0 of 0 entries

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance
No data available in table

Filter rows:

Showing 1 to 1 of 1 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
ROS1 fusion	lung non-small cell carcinoma	predicted - sensitive	Taletrectinib	Phase I	Actionable	In a Phase I trial, Taletrectinib (DS6051b) was well-tolerated and demonstrated some preliminary efficacy in patients with advanced solid tumors, including a partial response in a patient with non-small cell lung cancer liver metastases harboring a ROS1 fusion (Cancer Res 2016;76(14 Suppl):Abstract nr CT024; NCT02279433).	detail...

Showing 1 to 1 of 1 entries

Filter rows:

Reference Detail

Contact

Filtering

Sorting